Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Pfizer's stock is cheap but faces operational challenges. Analyze its valuation and performance to make informed investment ...

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Value stocks offer good opportunities for long-term investment in 2025, especially for investors who want stability and growth. Value stocks usually have lower ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher ...

Despite its apparently cheap valuation and a healthy dividend yield of 6.7%, these factors make Pfizer stock a difficult Hold in the months ahead, so I am neutral. Last week, The Wall Street ...

Here are three reasons why Pfizer could prove to be a steal of a deal this year. Buying quality stocks at decent valuations can give you a good margin of safety and minimize your investment risk. And ...

Pfizer (PFE) is one of the stocks most watched ... Without considering a stock's valuation, no investment decision can be efficient. In predicting a stock's future price performance, it's crucial ...